STARSOURCE MULTITRADE LIMITED — Annual Report 2020

Jun 26, 2020

==> picture [452 x 90] intentionally omitted <==

Date: 26[th] June, 2020

To, Bombay Stock Exchange Limited Department of Corporate Services 25[th] Floor, P. J. Towers, Dalal Street, Mumbai-400 001

Script ID: 506365

SUBJECT: SUBMISSION OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31/03/2020, DECLARATION, FORM ‘A’ AND AUDITORS REPORT IN BOARD MEETING HELD ON 26[TH] JUNE, 2020

Dear Sirs,

Pursuant to Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held on Friday, 26[th] June, 2020 at 04:00 P.M. at Empire House, 3[rd] Floor, 214, Dr. D. N. Road, Fort, Mumbai – 400 001 approved the following:

1. Standalone Financial Results for the quarter and year ended 31[st ] March, 2020

2. Form ‘A’ for the year ended 31[st ] March, 2020

3. Auditors Report on Standalone Financial Results for the year ended 31[st ] March, 2020

4. Declaration regarding Audit Report with unmodified opinion

The Company will not be publishing these Financial Results in the newspaper under Regulation 47 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, in view of SEBI Circular dated 12[th] May, 2020 vide circular no. SEBI/HO/CFD/CMD1/CIR/P/2020/79 and on account of the lock-down restrictions imposed by the Government of India.

Thanking You.

Yours Faithfully,

==> picture [235 x 118] intentionally omitted <==

==> picture [452 x 90] intentionally omitted <==

FORM A as per Regulation 33 (3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

1.	Name of the Company:	CHEMO PHARMA LABORATORIES LIMITED
2.	Annual Financial Statements for the year ended	31~~st~~March, 2020
3.	Type of Audit observation	Un-Qualified
4.	Frequency of observation	-
5.	To be signed by-  CEO – SHREENIWAS SOMANI  CFO – ASHOK SOMANI
	 Auditor of the Company –VMD & Co.  Audit Committee Chairman–Balkishan Lohia

==> picture [87 x 64] intentionally omitted <==

==> picture [469 x 93] intentionally omitted <==

DECLARATION

Declaration regarding Un-Modified Audit Report in respect Standalone Financial Statements for the Financial Year 2019-2020 under SEBI (Listing Obligations and Disclosure Requirements)(Amendment) Regulations, 2016

We hereby declare that we have submitted the Audit Reports in respect of Standalone Financial Statements for the year 2019-2020, along with the Financial Results on 26[th] June, 2020. We hereby confirm that auditors have expressed an Un-modified Opinion in their Audit Reports on Standalone Financial Statements

==> picture [442 x 483] intentionally omitted <==

----- Start of picture text -----

CHEMO PHARMA
1.
Name of the Company: LABORATORIES LIMITED
2. Annual Financial Statements for the 31 [st] March, 2020
year ended
3. Type of Audit observation Un-Qualified
4. Frequency of observation -
5. To be signed by-
 CEO – SHREENIWAS SOMANI
 CFO – ASHOK SOMANI
 Auditor of the Company – VMD & Co.
 [Audit Committee Chairman–Balkishan ]
Lohia
----- End of picture text -----

==> picture [612 x 83] intentionally omitted <==

AUDITOR’S REPORT ON QUARTERLY FINANCIAL RESULTS AND YEAR TO DATE RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To the Board of Directors of CHEMO PHARMA LABORATORIES LIMITED

We have audited the quarterly financial results of Chemo Pharma Laboratories Limited for the quarter ended March 31, 2020 and the year to date results for the period April 1, 2019 to March 31, 2020 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company’s management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted inIndia.

We have conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for ouropinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

• i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

• ii. give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2020 as well as the year to date results for the period from April 1, 2019 to March 31, 2020.

For VMD & Co. Chartered Accountants FRN: 125002W

CA Amit Ganpule Partner MRN: 114222 Place : Mumbai Date: June 26, 2020

UDIN:

==> picture [428 x 47] intentionally omitted <==

STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31[ST] MARCH, 2020

			(Rupees in Thousansd)	(Rupees in Thousansd)	(Rupees in Thousansd)	(Rupees in Thousansd)	(Rupees in Thousansd)
Sr. No.		Particulars	Quarter Ended			Year Ended
			31st March 2020	31st Dec., 2019	31st March 2019	31st March 2019	31st March 2020
			Un-audited	Un-audited	Un-audited	Audited	Audited
I II III	Rev	enue from Operations			-	-	-
	Oth	er Income	2,859	1,499	4,266	8,225	9,967
	Tot	al Revenue(I + II)	2,859	1,499	4,266	8,225	9,967
IV	Exp	enses
	(1)	Cost Materials consumed	-	-	-	-	-
	(2)	Purchase of Stock-in-Trade	-	-	-	-	-
	(3)	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-
	(4)	Finance Costs	-		-	-	-
	(5)	Employee Benefits Expenses	404	574	526	2,218	1,813
	(6)	Depreciation and Amortisation Expenses	231	-	-	47	231
	(7)	Administrative and Other Expenses	1,253	242	854	3,414	2,982
		i)Professional Charges	-	-	-	-	-
	Tot	ii)Share RegistryExpenses	-	-	-	-	-
		iii)Annual ListingFees	-	-	-	-	-
		iv)Postal Charges	-	-	-	-	-
		al Expenses	1,888	816	1,380	5,679	5,026
V	Pro and	fit/(Loss) before Exceptional and Extra ordinary Items tax (III - IV)	971	683	2,886	2,546	4,941
VI	Exc	eptional Items	-	-	-	-	-
VII	Net VI)	Profit/(Loss) before Extra ordinary Items and Tax (V -	971	683	2,886	2,546	4,941
VIII	Ext	ra Ordinary Items	-	-	-	-	-
IX	Pro	fit/(Loss) before Tax(VII-VIII)	971	683	2,886	2,546	4,941
X	Tax	Expenses
	(1)	Current Tax	760	-	460	460	760
	(2)	Tax Adjusted Previous Year	30	-	-	23	30
	(3)	Deffered Tax	-	-	-	-	-
XI	Pro	fit/(Loss) for the period from continuing operations (IX - X)	181	683	2,426	2,063	4,151
XII	Pro	fit/(Loss)from discontinuingoperations	-	-	-	-	-
XIII	Tax	Expenses of discontinuingoperations	-	-	-	-	-
XIV	Pro XIII	fit/(Loss) from discontinuing operations (after tax) (XII - )	-	-	-	-	-
XV	Pro	fit/(Loss) for theperiod(XI - XIV)	181	683	2,426	2,063	4,151
XVI	Oth A (i (ii) pro B (i (ii) pro	er Comprehensive Income ) Itmes that will not be reclassified to profit or loss Income rax relating to items that will not be reclassified to fit or loss ) Itmes that will not be reclassified to profit or loss Income rax relating to items that will not be reclassified to fit or loss	-	-	-	-	-
XVII	Tot (Co the	al Comprehensive Income for the period (XV+XVI) mprising Profit (Loss) and Other Comprehensive Incoe for period	181	683	2,426	2,063	4,151
XVIII	Ear Bas	nings per Share :(1) ic (2) Diluted	0.12	0.46	1.62	1.38	2.77

Notes :

1 This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.

• 2 The above Standlone Audited Financial Results for the Quarter and Year Ended 31.03.2020 have been reviewed by the Audit Committee in their Meeting held on 26.06.2020 and approved by the Board of Directors of its Meeting held on 26.06.2020. The Audit Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.

• 3 The Company is not having any Subsidary Company.

• 4 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

For Chemo Pharma Laboratories Limited Ashok Somani Director DIN : 03063364

==> picture [472 x 73] intentionally omitted <==

STANDALONE STATEMENT OF ASSETS & LIABILITIES AS ON 31ST MARCH, 2020

(Rupees in Thousands)

			(Rupees in Thousands)
Sr. No.	PARTICULARS	As at 31.03.2020 Audited	As at 31.03.2019 Audited
1 2	ASSETS Non-Current Assets (A) Property, Plant and Equipement (B) Financial Assets (i) Investment (ii) Loans Total Non-current Assets Current Assets (i) Cash & Cash Equivalents (ii) Fixed Deposits (iii) Other Current Assets Total Current Assets TOTAL ASSETS EQUITY AND LIABILTIES EQUITY (a) Equity Share Capital (b) Other Equity Total Equity Liabilities Non- Current Liabilities Current Liabilities (i) Borrowings (ii) Other Current Liabilities (iii) Provisions Total Current Liabilities TOTAL EQUITY AND LIABILITIES	747 237 19,568	30 369 18,417
		20,552 8,084 80,000 1,021	18,816 4,662 80,732 732
		89,105	85,394
		109,657	104,210
		15,000 92,447	15,000 88,296
		107,447	103,296
		- - 1,450 760	- - 1,259 (343)
		2,210	914
		109,657	104,210

By Order of the Board

For Chemo Pharma Laboratories Limited

Place : Mumbai Date : 26th June, 2020

ASHOK SOMANI DIRECTOR DIN : 03063364

==> picture [451 x 79] intentionally omitted <==

RECONCILIATON OF STANDALONE NET PROFIT FOR THE QUARTER & YEAR ENDED 31[ST] MARCH, 2020

	(Rs. in Thousands)	(Rs. in Thousands)
PARTICULARS	STANDALONE
	AUDITED QUARTER ENDED 31.03.2020	AUDITED YEAR ENDED 31.03.2020
Reconciliation of Profit After Tax as reported earlier:
Net Profit/ (Loss) for the Period(asper AS)	181	4,151
Benefit /(Charge):	-	-
Impact of Deferred Income(Government Grant)Amortized to Income	-	-
Impact of Fair Valuation of Financial Instruments	-	-
Impact of Actuarial Gain/Loss Taken OCI	-	-
Impact of Adjustment of Deferred Tax	-	-
Net Profit/ (Loss) for the Period(asper AS)	181	4,151

For Chemo Pharma Laboratories Ltd.

Ashok Somani Mumbai Director Date: 26th June, 2020 DIN : 03063364